Long-term, open-label, flexible-dose, extension study of vortioxetine in child and adolescent patients with Major Depressive Disorder (MDD) from 7 to 18 years of age
Latest Information Update: 06 Feb 2024
At a glance
- Drugs Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Lundbeck A/S
- 23 Feb 2023 This trial has been completed in Poland (End Date: 04 Apr 2022), according to European Clinical Trials Database record.
- 17 May 2022 Status changed from completed to discontinued. The study was terminated based on new efficacy data from another study.
- 05 May 2022 This trial has been completed in Spain (19 Apr 2022), according to European Clinical Trials Database record.